HIV treatment and prevention on every 2026 North Carolina Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 12 stand-alone Part D plans in North Carolina cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
12 plans, cheapest premium first. Scroll sideways for all of them →
| Drug | Wellcare Value Script$3.60/moS4802-143 | Wellcare Classic$4.70/moS4802-081 | Humana Basic Rx Plan$6.80/moS5884-133 | Humana Value Rx Plan$32.00/moS5884-187 | AARP Medicare Rx Saver from UHC$56.90/moS5921-353 | HealthSpring Extra Rx$78.00/moS5617-358 | Blue Medicare Rx Standard$83.90/moS5540-002 | SilverScript Choice$90.20/moS5601-016 | HealthSpring Assurance Rx$110.40/moS5617-217 | Humana Premier Rx Plan$110.90/moS5884-154 | AARP Medicare Rx Preferred from UHC$119.80/moS5921-390 | Blue Medicare Rx Enhanced$163.20/moS5540-004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biktarvybictegravir/emtricitabine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Dovatodolutegravir and lamivudine | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Triumeqabacavir/dolutegravir/lamivudine | Tier 440% | Tier 427% | Tier 432%QL 180/30d | Tier 434%QL 180/30d | Tier 434%QL 180/30d | Tier 431%QL 300/30d | Tier 432%QL 180/30d | Tier 433% | Tier 432%QL 300/30d | Tier 450%QL 180/30d | Tier 433%QL 180/30d | Tier 440%QL 180/30d |
| Genvoyaelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Odefseyemtricitabine/rilpivirine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Symtuzadarunavir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Julucadolutegravir and rilpivirine | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Descovyemtricitabine and tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Truvadaemtricitabine and tenofovir disoproxil | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| emtricitabine-tenofovirgeneric Truvada | Tier 440%QL 30/30d | Tier 427%QL 30/30d | Tier 432%QL 30/30d | Tier 434%QL 30/30d | Tier 434%QL 30/30d | Tier 431%QL 30/30d | Tier 432%QL 30/30d | Tier 433%QL 30/30d | Tier 432%QL 30/30d | Tier 450%QL 30/30d | Tier 433%QL 30/30d | Tier 440%QL 30/30d |
| Tivicaydolutegravir | Tier 525% | Tier 525% | Tier 525%QL 60/30d | Tier 526%QL 60/30d | Tier 525%QL 60/30d | Tier 431%QL 180/30d | Tier 525%QL 60/30d | Tier 525% | Tier 432%QL 180/30d | Tier 533%QL 60/30d | Tier 531%QL 60/30d | Tier 533%QL 60/30d |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.